


9/255 Response

LISTING OF CLAIMS

Claim 1 (currently amended): A compound of the formula (I):



(I)

wherein

 \mathbf{R}_1 is $-\text{CF}_3$, $-\text{CH}(\text{CH}_3)(\text{CF}_3)$, $-\text{CH}(\text{CF}_3)_2$, $-\text{OCF}_3$, $-\text{CF}_2\text{CF}_3$; \mathbf{R}_2 is C_{1-5} alkyl; \mathbf{R}_3 is attached at the 3- or 4-position on the phenyl ring and is hydrogen, $-\text{NH}_2$ or $\mathbf{R}_4-\text{S}(\text{O})_2\text{NH}-$ wherein \mathbf{R}_4 is chosen from C_{1-5} alkyl or carbocycle; \mathbf{W} is an N atom; \mathbf{X} is chosen from C1-5 alkyl or C1-5 alkoxy each optionally substituted by mono- or di- C1-3 alkyl amino;or \mathbf{X} is $-\text{N}(\mathbf{R}^a)_2$ wherein \mathbf{R}^a is independently chosen from hydrogen, C1-5 alkyl, aryl, aryl C1-3 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-3 alkyl and C1-5 alkoxy C1-5 alkyl each \mathbf{R}^a where possible is optionally substituted by one to two C1-5 alkyl, C1-5 alkoxy, hydroxy, halogen or amino optionally mono- or di-substituted by C1-3 alkyl;

9/255 Response

or the pharmaceutically acceptable acids, esters, salts or isomers thereof.

Claim 2 (previously amended): The compound according to claim 1 wherein:

R₁ is -CF₃, -CH(CH₃)(CF₃), -CH(CF₃)₂, -OCF₃ or -CF₂CF₃;

R₂ is C₁₋₃ alkyl;

X is chosen from

C₁₋₅ alkyl or C₁₋₅ alkoxy each optionally substituted by mono- or di-C₁₋₃ alkyl amino;

or **X** is -N(**R^a**)₂ wherein **R^a** is independently chosen from hydrogen, C₁₋₅ alkyl, phenylC₁₋₃ alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl C₁₋₃ alkyl and C₁₋₃alkoxyC₁₋₃alkyl each **R^a** where possible is optionally substituted by one to two C₁₋₃ alkyl, C₁₋₃ alkoxy, hydroxy, halogen or amino optionally mono- or di-substituted by C₁₋₂ alkyl.

Claim 3 (original): The compound according to claim 2 wherein:

R₁ is -CF₃, -CH(CH₃)(CF₃), -CH(CF₃)₂ or -CF₂CF₃;

R₂ is C₁₋₂ alkyl.

Claim 4(original): The compound according to claim 3 wherein:

R₁ is -CF₃;

R₂ is -CH₃.

Claim 5 (previously amended): The compound according to claim 4 wherein:

9/255 Response

X is chosen from

NH₂, NH(CH₃), -NHCH₂CH₂N(CH₃)₂, -NHCH₂CH₂-O-CH₃, -CH₂-N(CH₃)₂, -CH₂CH₂-N(CH₃)₂, -CH₂CH₂CH₂-N(CH₃)₂, -CH₂CH₂CH₂CH₂-N(CH₃)₂, -CH₂-NH(CH₃), -CH₂CH₂-NH(CH₃), -CH₂CH₂CH₂-NH(CH₃), -CH₂CH₂CH₂CH₂-NH(CH₃), -O-CH₂-N(CH₃)₂, -O-CH₂CH₂-N(CH₃)₂, -O-CH₂CH₂CH₂-N(CH₃)₂, -O-CH₂CH₂CH₂CH₂-N(CH₃)₂, -OCH₂-NH(CH₃), -O-CH₂CH₂-NH(CH₃), -O-CH₂CH₂CH₂-NH(CH₃) and -O-CH₂CH₂CH₂CH₂-NH(CH₃) .

Claim 6 (previously amended): The compound according to claim 5 wherein:

X is chosen from

NH₂, NH(CH₃), -NHCH₂CH₂N(CH₃)₂, -NHCH₂CH₂-O-CH₃, -CH₂-N(CH₃)₂, -CH₂CH₂-N(CH₃)₂, -CH₂CH₂CH₂-N(CH₃)₂, -CH₂CH₂CH₂CH₂-N(CH₃)₂, -CH₂-NH(CH₃), -CH₂CH₂-NH(CH₃), -CH₂CH₂CH₂-NH(CH₃), -CH₂CH₂CH₂CH₂-NH(CH₃), -O-CH₂-N(CH₃)₂, -O-CH₂CH₂-N(CH₃)₂, -O-CH₂CH₂CH₂-N(CH₃)₂, -O-CH₂CH₂CH₂CH₂-N(CH₃)₂, -OCH₂-NH(CH₃), -O-CH₂CH₂-NH(CH₃), -O-CH₂CH₂CH₂-NH(CH₃) and -O-CH₂CH₂CH₂CH₂-NH(CH₃) .

Claim 7 (currently amended): A compound chosen from:

1-[4-(2-Amino-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-(2-methoxy-5-trifluoromethyl-phenyl)-urea;
1-[4-[2-(2-Dimethylamino-ethylamino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl]-3-(2-methoxy-5-trifluoromethyl-phenyl)-urea;
1-[4-[2-(2-Methoxy-ethylamino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl]-3-(2-methoxy-5-trifluoromethyl-phenyl)-urea;
1-[4-(2-Cyclopropylamino-6-methyl-pyrimidin-4-yloxy)-

9/255 Response

naphthalen-1-yl]-3-(2-methoxy-5-trifluoromethyl-phenyl)-urea;
1-[4-[2-(2-Methoxy-1-methyl-ethylamino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl]-3-(2-methoxy-5-trifluoromethyl-phenyl)-urea;
1-[4-[2-(2,3-Dihydroxy-propylamino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl]-3-(2-methoxy-5-trifluoromethyl-phenyl)-urea;
1-[4-(2,6-Dimethyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-(2-methoxy-5-trifluoromethyl-phenyl)-urea;
1-[4-(2-Methoxy-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-(2-methoxy-5-trifluoromethyl-phenyl)-urea and
N-(3-{3-[4-(2,6-Dimethyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-2-methoxy-5-trifluoromethyl-phenyl)-methanesulfonamide

or the pharmaceutically acceptable acids, esters, salts or isomers thereof.

Claim 8 (currently amended): A compound chosen from:

1-[4-(2-Ethylamino-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-(2-methoxy-5-trifluoromethyl-phenyl)-urea;
1-[4-[2-(Cyclopropylmethyl-amino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl]-3-(2-methoxy-5-trifluoromethyl-phenyl)-urea;
1-[4-(2-Isopropylamino-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-(2-methoxy-5-trifluoromethyl-phenyl)-urea;
1-[4-(2-Amino-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-[2-methoxy-5-(2,2,2-trifluoro-1-methyl-ethyl)-phenyl]-urea;
1-[4-(2-Amino-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-[2-methoxy-5-(2,2,2-trifluoro-1-trifluoromethyl-ethyl)-phenyl]-urea;

9/255 Response

1-[4-(2-Amino-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-[2-methoxy-5-(2,2,2-trifluoro-ethyl)-phenyl]-urea;
1-[4-(2-Methylamino-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-(2-methoxy-5-trifluoromethoxy-phenyl)-urea;
1-(2-Methoxy-5-trifluoromethoxy-phenyl)-3-[4-(6-methyl-2-ethylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;
1-{4-[2-(2-Dimethylamino-ethylamino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl}-3-(2-methoxy-5-trifluoromethoxy-phenyl)-urea;
1-{4-[2-(2-Methoxy-ethylamino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl}-3-(2-methoxy-5-trifluoromethoxy-phenyl)-urea;
1-[4-(2-Dimethylaminomethyl-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-(2-methoxy-5-trifluoromethoxy-phenyl)-urea;
1-{4-[2-(3-Dimethylamino-propylamino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl}-3-[2-methoxy-5-(2,2,2-trifluoro-ethyl)-phenyl]-urea;
1-[4-(2-Amino-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-(2-methoxy-5-pentafluoroethyl-phenyl)-urea;
1-{4-[2-(Cyclopropylmethyl-amino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl}-3-(2-methoxy-5-trifluoromethyl-phenyl)-urea;
1-{4-[2-(2-Dimethylamino-ethylamino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl}-3-[2-methoxy-5-(2,2,2-trifluoro-1-trifluoromethyl-ethyl)-phenyl]-urea; and
1-[4-(2-Dimethylaminomethyl-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-(2-methoxy-5-trifluoromethyl-phenyl)-urea

or the pharmaceutically acceptable acids, esters, salts or isomers thereof.

Claim 9 (currently amended): A compound chosen from

9/255 Response

1-[4-(2-Amino-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-(2-methoxy-5-trifluoromethyl-phenyl)-urea;
1-(2-Methoxy-5-trifluoromethyl-phenyl)-3-[4-(6-methyl-2-methylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;
1-{4-[2-(2-Dimethylamino-ethylamino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl}-3-(2-methoxy-5-trifluoromethyl-phenyl)-urea and
1-{4-[2-(2-Methoxy-ethylamino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl}-3-(2-methoxy-5-trifluoromethyl-phenyl)-urea;

or the pharmaceutically acceptable acids, esters, salts or isomers thereof.

Claim 10 (original): A pharmaceutical composition containing a pharmaceutically effective amount of a compound according to claim 1 and one or more pharmaceutically acceptable carriers and/or adjuvants.


Claim 11 (cancelled).

Claim 12 (currently amended): A method of treating a disease or condition selected from rheumatoid arthritis, ~~inflammatory bowel disease, septic shock, osteoarthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, Guillain-Barre syndrome, psoriasis, graft versus host disease, systemic lupus erythematosus, restenosis following percutaneous transluminal coronary angioplasty, diabetes, toxic shock syndrome, Alzheimer's disease, acute and chronic pain, contact dermatitis, atherosclerosis, traumatic arthritis, glomerulonephritis, reperfusion injury, sepsis, bone resorption diseases, and chronic obstructive pulmonary disease, congestive heart failure, asthma, stroke, myocardial infarction, thermal injury, adult respiratory distress syndrome (ARDS), multiple organ injury secondary to trauma, dermatoses with acute inflammatory components, acute purulent meningitis, necrotizing enterocolitis and syndromes associated with hemodialysis, leukopheresis and granulocyte transfusion~~ comprising administering to a patient a pharmaceutically effective amount of a compound according to claim 1.

9/255 Response


Claim 13 (original): A process for preparing compounds of the formula (I) according to claim 1, wherein:

a) an arylamine of formula IIa and an arylisocyanate of formula III is dissolved in a non-protic, anhydrous solvent chosen from THF, ether, toluene, dioxane or ethyl acetate, between 0 - 45° C, for 2-24 h, and subsequently isolating the product of formula I or precursors thereof;



or


b) dissolving an arylamine of formula IIa in a halogenated solvent, diluting the mixture with aqueous alkali and combining with phosgene to provide the corresponding isocyanate, mixing the isocyanate and arylamine IV in a non-protic, anhydrous solvent selected from THF, ether, toluene, dioxane, dichloromethane or ethyl acetate at between about 0 - 45° C and subsequently isolating to provide the product of formula I or precursors thereof;



or

9/255 Response

c) dissolving an arylamine of formula IIa in a suitable halogenated solvent optionally adding a suitable base followed by an alkyl or aryl chloroformate between 0 - 85°C, for 2 - 24 h, providing carbamate V, mixing carbamate V and arylamine IV in a non-protic, anhydrous solvent selected from THF, ether, toluene, dioxane, dichloromethane or ethyl acetate, between 0 - 110°C, for 2 - 24 h, subsequently isolating to provide the product of formula I or precursors thereof;



or

d) dissolving an aromatic carboxylic acid in a non-protic solvent and an inorganic base, cooling the mixture is to -30- 0°C, adding an alkyl chloroformate at 0°C for 1-3 hours, adding sodium azide in water diluted with toluene followed by heating for 1-4 hours, cooling to room temperature to give isocyanate (Va), reacting isocyanate (Va) with amine (IV), subsequently isolating to give product of formula I or precursors thereof;

